体外二氧化碳去除（ECCOR）在急性呼吸衰竭患者中的应用。
Extracorporeal carbon dioxide removal (ECCOR) in patients with acute respiratory failure.
机构信息
Department of Anesthesiology and Intensive Care, Policlinico Umberto 1, Sapienza University of Rome, Rome, Italy.
Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
出版信息
Intensive Care Med. 2017 Apr;43(4):519-530. doi: 10.1007/s00134-016-4673-0. Epub 2017 Jan 28.
PURPOSE
To review the available knowledge related to the use of ECCOR as adjuvant strategy to mechanical ventilation (MV) in various clinical settings of acute respiratory failure (ARF).
METHODS
Expert opinion and review of the literature.
RESULTS
ECCOR may be a promising adjuvant therapeutic strategy for the management of patients with severe exacerbations of COPD and for the achievement of protective or ultra-protective ventilation in patients with ARDS without life-threatening hypoxemia. Given the observational nature of most of the available clinical data and differences in technical features and performances of current devices, the balance of risks and benefits for or against ECCOR in such patient populations remains unclear CONCLUSIONS: ECCOR is currently an experimental technique rather than an accepted therapeutic strategy in ARF-its safety and efficacy require confirmation in clinical trials.
目的
回顾与 ECCOR 在急性呼吸衰竭（ARF）各种临床情况下作为机械通气（MV）辅助策略的使用相关的现有知识。
方法
专家意见和文献回顾。
结果
ECCOR 可能是治疗 COPD 严重恶化和在无危及生命性低氧血症的 ARDS 患者中实现保护性或超保护性通气的有前途的辅助治疗策略。鉴于大多数现有临床数据的观察性性质以及当前设备的技术特征和性能差异，ECCOR 在这些患者人群中的风险和收益平衡尚不清楚。
结论
ECCOR 目前是 ARF 中的一项实验性技术，而不是一种被接受的治疗策略——其安全性和疗效需要临床试验的证实。
Zotero 插件